SUNRISE, Fla., Dec 6, 2011 (GlobeNewswire via COMTEX) — Bioheart, Inc. (BHRT.OB) announced that they have completed an Investigational New Drug (IND) application to the FDA for the ANGEL trial.
International Cellular Medicine Society and Regenerative Medicine Institute enter formal agreements to begin Accreditation Process.
Bioheart Announces Cell Therapies Program in Latin America for Congestive Heart Failure and Peripheral Arterial Disease Patients
Bioheart Commenced Successful Regenerative Stem Cell Treatments
Retired NFL Great Bart Oates has Joined the Lineup of Professional Athletes Seeking Stem Cell Treatment Abroad.
Reprogramming Cells Leads to Genomic Aberrations, Study Finds
